Atrium Therapeutics, Inc. - RNA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G | RA Capital Management, L.P. | 5.6% | 864,102 | View |
| May 15, 2026 | SCHEDULE 13G | Peter Kolchinsky | 5.6% | 864,102 | View |
| May 15, 2026 | SCHEDULE 13G | Rajeev Shah | 5.6% | 864,102 | View |
| May 15, 2026 | SCHEDULE 13G | RA Capital Healthcare Fund, L.P. | 5.6% | 864,102 | View |
| Apr 08, 2026 | SCHEDULE 13G | T. Rowe Price Associates, Inc. | 10.0% | 1,553,210 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.